A combined smoking cessation intervention within a lung cancer screening trial: A pilot observational study

Tumori

Volumn 101, Issue 3, 2015, Pages 306-311

  Pozzi, Paolo ^a   Munarini, Elena ^a   Bravi, Francesca ^b   Rossi, Marta ^b,c   La Vecchia, Carlo ^b,c   Boffi, Roberto ^a   Pastorino, Ugo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Lung cancer screening; Primary prevention; Smoking cessation

Indexed keywords

PLACEBO; VARENICLINE; AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; NICOTINE GUM; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ABNORMAL DREAMING; ADULT; AGED; ARTICLE; BODY MASS; CANCER SCREENING; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; FEASIBILITY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INSOMNIA; INTERVENTION STUDY; IRRITABILITY; LUNG CANCER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT COUNSELING; PILOT STUDY; PREVALENCE; PROPENSITY SCORE; PROSPECTIVE STUDY; RELAPSE; SELF CONCEPT; SMOKING CESSATION; TOBACCO DEPENDENCE; ADVERSE EFFECTS; EARLY DIAGNOSIS; FOLLOW UP; ITALY; LUNG NEOPLASMS; MASS SCREENING; MIDDLE AGED; PROCEDURES; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SMOKING; THERAPY; TOBACCO USE DISORDER; TREATMENT OUTCOME;

AGED; BENZAZEPINES; BUPROPION; DOPAMINE UPTAKE INHIBITORS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; NICOTINIC AGONISTS; PILOT PROJECTS; PROPENSITY SCORE; PROSPECTIVE STUDIES; QUINOXALINES; SEVERITY OF ILLNESS INDEX; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84938284107     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000282     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Fer lay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354(9173):99-105.
3. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality wi th low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
4. Ostroff JS, Buckshee N, Mancuso CA, Yankelevitz DF, Henschke CI. Smoking cessation following CT screening fo r early detection of lung cancer. Prev Med. 2001;33(6):613-621.
5. Cox LS, Clark MM, Jett JR, et al. Change in smoking status after spiral chest computed tomography scan screening. Cancer. 2003;98(11):2495-2501.
6. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung car cinoma screening. Cancer. 2005;103(10):2154-2162.
7. Ashraf H, Tø nnesen P, Holst Pedersen J, Dirksen A, Thorsen H, Døssing M. Effect of CT screening on smoking habits at 1-year follo w-up in the Danish Lung Cancer Screening Trial (DLCST). Thorax. 2009;64(5):388-392.
8. van der Aalst CM,van den Bergh KA,Willemsen MC,de Koning HJ,van Klaveren RJ. Lung cancer screen ing and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial Thorax.,2010, 65, 7, 600-605.
9. Centers for Disease Control and Prevention (CDC). Quitting smoking among adults: United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011;60(44):1513-1519.
10. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6(11):1841-1848.
11. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-2429.
12. van der Aalst CM, van Klaveren RJ, van den Bergh KA, Willemsen MC, de Koning HJ. The impact of a lung cancer computed tomography screening result on smoking abstinence. Eur Respir J. 2011;37(6):1466-1473.
13. Ferketich AK, Otterson GA, King M, Hall N, Browning KK, Wewers ME. A pilot test of a combined tobacco dependence treatment and lung cancer screening program. Lung Cancer. 2012;76(2):211-215.
14. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Pub lic Health Service report. Am J Prev Med. 2008;35(2):158-176.
15. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an ?4?2 nicotinic acetylcholine receptor parti al agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
16. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phas e 3 Study Group. Efficacy of varenicline, an ?4?2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.
17. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308-315.
18. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
19. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
20. Jarvis MJ, Russell MA, Saloojee Y. Expired air carbon monoxide: a simple breath test of tobacco smoke intake. BMJ. 1980;281(6238):484-485.
21. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest. 2000;117(3):758-763.
22. Rosenbaum PR. Propensity score. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics, volume 5. New York: John Wiley and Sons; 1998:3551-3555.
23. Cavuto S, Bravi F, Grassi MC, Apolone G. Propensity score for the analysis of observational data. An introduction and an illustrative example. Drug Dev Res. 2006;67(3):208-216.
24. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100(3):299-303.
25. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-Analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
26. . Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2012;12:CD009670.
27. Hajek P, Tø nnesen P, Arteaga C, Russ C, Tonstad S. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction. 2009;104(9):1597-1602.
28. Boeri M,Verri C,Conte D,et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer Proc Natl Acad Sci USA. 2011, 108, 9, 3713-3718.